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Background: Plumbagin, a naphthoquinone extracted from the officinal leadwort presenting
promising anti-cancer properties, has its therapeutic potential limited by its inability to reach
tumors in a specific way at a therapeutic concentration following systemic injection. The
purpose of this study is to assess whether a novel tumor-targeted, lipid–polymer hybrid
nanoparticle formulation of plumbagin would suppress the growth of B16-F10 melanoma
in vitro and in vivo.
Methods: Novel lipid–polymer hybrid nanoparticles entrapping plumbagin and conjugated
with transferrin, whose receptors are present in abundance on many cancer cells, have been
developed. Their cellular uptake, anti-proliferative and apoptosis efficacy were assessed on
various cancer cell lines in vitro. Their therapeutic efficacy was evaluated in vivo after tail
vein injection to mice bearing B16-F10 melanoma tumors.
Results: The transferrin-bearing lipid–polymer hybrid nanoparticles loaded with plumbagin
resulted in the disappearance of 40% of B16-F10 tumors and regression of 10% of the
tumors following intravenous administration. They were well tolerated by the mice.
Conclusion: These therapeutic effects, therefore, make transferrin-bearing lipid–polymer
hybrid nanoparticles entrapping plumbagin a highly promising anti-cancer nanomedicine.
Keywords: plumbagin, transferrin, tumor targeting, lipid–polymer hybrid nanoparticles,
cancer therapy
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Plumbagin (5-hydroxy-2-methyl-naphthalene-1,4-dione), a naphthoquinone
extracted from the roots of the Plumbago indica plant (known as officinal leadwort
and widely used in traditional Chinese medicine),1 has recently attracted consider
able interest due to its chemopreventive and therapeutic efficacy against many types
of cancer, including breast,2 ovarian,3 lung,4 prostate5 and melanoma.6 Its anticancer effect was shown to occur through a wide range of mechanisms, such as the
generation of reactive oxygen species, the decrease in intracellular glutathione
levels and the activation of p53. Plumbagin also inhibits the nuclear factor-κB (NFkB), the signal transducer and activator of transcription 3 (STAT3), the p38 mito
gen-activated protein kinase (MAPK) and the phosphoinositide 3-kinase (PI3K)/the
protein kinase B/Akt (PKB/AKT)/the mammalian target of rapamycin (mTOR)
signaling molecules, c-Jun N-terminal kinase, resulting in potentiation of
apoptosis.4,7–11
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The therapeutic use of plumbagin has however been
hampered so far, due to its high lipophilicity (log
P 3.04),12 limited solubility in water (79 μg/mL)12 and
lack of stability, which limited its biopharmaceutical appli
cations. Furthermore, this drug failed to specifically reach
tumors at a therapeutic concentration and was rapidly
eliminated, with a short biological half-life of 35.89 ±
7.95 min.13
This drawback could be overcome by loading the drug
within delivery systems able to entrap this lipophilic drug,
enhance its water solubility and its circulation time and
release it in a sustained way, thus lowering the frequency
of administration and the occurrence of secondary effects
of the drug.
Several lipid-based vesicles (thermosensitive and poly
ethylene glycol (PEG)-modified liposomes)13,14 and poly
mer-based nanoparticles (poly(lactic-co-glycolic acid)
(PLGA) microspheres and PLGA-PEG nanoparticles)15,16
have previously been investigated to enhance the thera
peutic potential of plumbagin, but with limited effects on
the anti-cancer efficacy of plumbagin so far.
We now would like to develop novel lipid-polymer
hybrid nanoparticles combining distinct characteristics of
PEGylated liposomes and polymeric nanoparticles: (i) an
hydrophobic polymer core that is biocompatible, biode
gradable and capable of carrying the poorly water-soluble
plumbagin and controlling its release; (ii) a lipid layer
that can reduce water penetration rate into the nanoparti
cles, while at the same time preventing the entrapped drug
from freely diffusing out of the nanoparticles; (iii) an
hydrophilic PEG shell that can prevent a rapid clearance
of the delivery system by mononuclear phagocytic sys
tem, improving the blood circulation half-life of the
drug.17 Furthermore, as iron is essential for the growth
of cancer cells and can be carried to tumors by transferrin
(Tf), whose receptors are overexpressed on many cancer
cell lines,18–23 we hypothesize that conjugating lipidpolymer hybrid nanoparticles with transferrin would
increase the delivery of plumbagin by active targeting to
the cancer cells, thus leading to its enhanced therapeutic
efficacy. The combination of transferrin with the passive
accumulation of lipid-polymer hybrid nanoparticles in
tumors as a result of the enhanced permeability and reten
tion (EPR) effect24 is expected to provide tumor-selective
targeting of the lipid-polymer hybrid nanoparticles to the
cancer cells.
The objectives of this study were therefore 1) to develop
and characterize plumbagin-entrapping lipid-polymer hybrid
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nanoparticles conjugated with transferrin, 2) to evaluate their
uptake, anti-proliferative and apoptosis efficacy on various
cancer cell lines in vitro and 3) to assess their therapeutic
efficacy in vivo, following systemic administration to tumorbearing mice.

Materials and Methods
Cell Lines and Reagents
Plumbagin
(5-hydroxy-2-methyl-1,4-naphthoquinone,
from Plumbago indica), hydrogenated phosphatidylcho
line (HPC), human holo-transferrin (Tf), Resomer® RG
503 H (acid-terminated poly(lactide-co-glycolide) (PLGACOOH), lactide: glycolide 50:50, viscosity 0.32–0.44 dL/
g, MW 24 000–38 000 Da) and all other chemicals not
specifically mentioned below were purchased from Sigma
Aldrich (Poole, UK). 1,2-distearoyl-sn-glycero-3-phos
phoethanolamine-N-[maleimide (polyethylene glycol)2000] (DSPE-PEG2K-MAL) came from Jenkem
Technology (Plano, TX). Dulbecco’s Modified Eagle
Medium (DMEM) and Roswell Park Memorial Institute
1640 (RPMI-1640) cell culture media, fetal bovine serum
(FBS), L-glutamine and penicillin-streptomycin were pur
chased from Invitrogen (Paisley, UK). A431 human epi
dermoid carcinoma and T98G glioblastoma were obtained
from the European Collection of Cell Cultures (Salisbury,
UK), while Bioware® B16-F10-luc-G5 mouse melanoma
expressing the firefly luciferase was purchased from
Caliper Life Sciences (Hopkinton, MA). BD
Pharmingen® Fluorescein isothiocyanate (FITC) Annexin
V Apoptosis Detection Kit I was obtained from BD
Biosciences (San Jose, CA).

Preparation and Optimization of Lipid–
Polymer Hybrid Nanoparticles Entrapping
Plumbagin
Lipid–polymer hybrid nanoparticles (LPN) entrapping
plumbagin were prepared by shaking a mixture of hydro
genated phosphatidylcholine (2 mg) and DSPE-PEG2KMAL (3 mg) at molar ratios of 70:30, in 5 mL deionized
water at 65°C for 1 h. PLGA-COOH (25 mg) and plum
bagin (2.5 mg) in acetone (2.5 mL) were then added
dropwise under moderate stirring. The mixture was stirred
overnight at 25°C to evaporate all the organic solvent. The
nanoparticles were then collected by centrifugation at 7
500 rpm (6 600 g) at 20°C for 30 min (Hermle® Z323K
centrifuge, Wehingen, Germany), using Vivaspin® 20 cen
trifuge tubes (molecular weight cut-off: 100 000 Daltons)
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(Sartorius Ltd., Epsom, UK). They were washed twice
with deionized water (2 mL) to remove excess plumbagin,
before being re-suspended in deionized water (1 mL) and
stored at 4°C.
The nanoparticles were optimized by varying two fac
tors: (1) the weight ratio of lipid (HPC and DSPE-PEG2KMAL) to PLGA-COOH polymer (1:10, 2:10, 4:10, 6:10,
8:10 and 10:10) and (2) the molar ratio of HPC to DSPEPEG2K-MAL (90:10, 85:15, 80:20, 70:30, 60:40 and
50:50), while fixing the theoretical drug loading at 10%
of polymer weight, the concentration of polymer in
organic solvent at 10 mg/mL and the volume ratio of
water to organic solvent at 2:1.
To determine the entrapment efficiency of plumbagin,
the nanoparticles (10 µL) were disrupted with isopropanol
(990 µL), followed by centrifugation at 10 000 rpm (9 300
g) for 10 min with an IEC Micromax® centrifuge
(ThermoFisher Scientific, Waltham, MA). The amount of
plumbagin in the supernatant was determined by spectro
photometry (λmax: 420 nm), by using an Agilent Varian
Cary®
50
UV-Vis
spectrophotometer
(Agilent
Technologies, Santa Clara, CA). The results were
expressed as percentage entrapment efficiency.

Preparation of Transferrin-Bearing Lipid–
Polymer Hybrid Nanoparticles Entrapping
Plumbagin
Tf was conjugated to the LPN using the thiol–maleimide
“click” reaction. To do so, Tf (10 mg) dissolved in sodium
phosphate buffer (50 mM) containing sodium chloride
(150 mM) (pH 8, 1 mL), was thiolated following incuba
tion with 10-fold molar excess of 2-iminothiolane (85 µL
of Traut’s reagent, 2 mg/mL in distilled water) at 25°C for
2 h whilst stirring. The thiolated Tf was then separated
from unreacted Traut’s reagent by centrifugation at 9
500 rpm (10 500 g) at 20°C for 15 min (Hermle® Z323K
centrifuge, Wehingen, Germany), with Vivaspin® 6 centri
fuge tubes (molecular weight cut-off: 5 000 Daltons)
(Sartorius Ltd., Epsom, UK). It was immediately conju
gated to the LPN and incubated for 2 h at 25°C whilst
stirring. Unreacted Tf was then removed from the resulting
LPN by centrifugation at 7 500 rpm (6 600 g) at 20°C for
15 min, with Vivaspin® 6 centrifuge tubes (molecular
weight cut-off: 100 000 Daltons) (Sartorius Ltd.,
Epsom, UK).
The formation of LPN was visualized by transmission
electron microscopy (TEM). Briefly, Formvar/Carbon-
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coated copper grids (400 mesh) were glow discharged.
Each sample (3 µL) was then dropped onto the hydrophilic
support film. Dried samples were imaged using the JEOL
1200 transmission electron microscope (JEOL USA, Inc.,
Peabody, MA) operating at 80 kV fitted with a Gatan 794
MultiScan® camera (Gatan, Pleasanton, CA).
The amount of Tf conjugated to the LPN was deter
mined by Lowry assay,25 using a previously reported
method.26
The hydrodynamic size and zeta potential of LPN were
measured by photon correlation spectroscopy and laser
Doppler electrophoresis, with a Zetasizer Nano-ZS®
(Malvern Instruments, Malvern, UK).

Plumbagin Release from the TransferrinBearing Lipid–Polymer Hybrid
Nanoparticles
The release of plumbagin was studied using a dialysis
method at pHs 7.4 and 5.5, respectively mimicking the
physiological pH in normal tissues and blood, and the
extracellular microenvironment of tumor tissues. To do
so, plumbagin (500 µg/mL in phosphate buffer for
1 mL) either formulated as Tf-bearing LPN, control
LPN or in solution, was transferred into a SnakeSkin®
dialysis bag (molecular weight cut-off: 3 500 Daltons)
(ThermoFisher Scientific, Waltham, MA) and was dia
lyzed against 50 mL of phosphate buffer pHs 7.4 and
5.5. The samples were kept at 37°C with continuous
stirring (100 rpm). At specific time intervals (30 min,
then every hour for the first 6 h (1 h, 2 h, 3 h, 4 h, 5 h,
6 h), then every 2 h for the next 6 h (8 h, 10 h, 12 h),
and 24 h), 1 mL of the dialysate was withdrawn in
triplicates and then replaced with an equal volume of
fresh buffer. The amount of plumbagin in the sample
was determined by spectrophotometry (Agilent
Technologies, Santa Clara, CA) and reported as
a percentage cumulative drug release.

Cell Culture
B16-F10-luc-G5 melanoma cell line was grown in RPMI1640 medium, while A431 human epidermoid carcinoma
and T98G glioblastoma cell lines were grown in DMEM
medium. Both media were supplemented with 10% (v/v)
fetal bovine serum, 1% (v/v) L-glutamine and 0.5% (v/v)
penicillin-streptomycin. Cells were cultured at 37°C in
a humid atmosphere of 5% CO2.
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Cellular Uptake
To investigate the intracellular accumulation of plumba
gin, cells were seeded at a density of 2 x 105 cells/well in
6-well plates. After 72 h, they were treated with plumba
gin (10 µg/well), either formulated as Tf-bearing LPN,
control LPN, or in solution (prepared from a stock plum
bagin solution of 100 mg/mL in DMSO), for 3 h.
Following incubation with the treatments, they were har
vested and washed twice with cold phosphate buffer saline
(PBS) (3 mL) to remove the nanoparticles that were not
taken up or bound to the cell surface. Cells were then lysed
with Triton-X (5%, 1 mL) and incubated at 37°C for 24
h before being centrifuged at 10 000 rpm (9 300 g) for 15
min with an IEC Micromax® centrifuge (ThermoFisher
Scientific, Waltham, MA). The amount of plumbagin in
the surfactant was determined by spectrophotometry (λmax:
420 nm), using a FlexStation 3® multi-mode microplate
reader (Molecular Devices, Sunnyvale, CA).
To further confirm the cellular uptake of LPN, plum
bagin was replaced with coumarin-6, a fluorescent lipophi
lic drug model (Supplementary Table 1, supplementary
information). Tf-bearing and control LPN entrapping cou
marin-6 were prepared and characterized using the same
protocol as described above. They were used for determin
ing the cellular uptake of coumarin-6 in B16-F10-luc-G5
cells.
Confocal microscopy was used for qualitative analysis
of the LPN uptake by the cells. In brief, B16-F10-luc-G5
cells were seeded in 6-well plates containing a glass cover
slip, at a density of 1 x 105 cells/well. They were grown
for 24 h before being treated with coumarin-6 (1 µg/well),
either entrapped in Tf-bearing LPN, control LPN or left in
solution. Following 2-h treatment, they were washed twice
with 3 mL cold PBS, followed by fixation with 2 mL
formaldehyde solution (3.7% in PBS) for 10 min at 25°
C. Subsequently, they were washed twice with 3 mL PBS,
then incubated with 3 mL Triton-X solution (0.1%) at 25°
C for 5 min, before adding 3 mL bovine serum albumin in
PBS (1% w/v) followed by incubation at 37°C for 30 min
to reduce the non-specific binding. The staining of the
cells was done with Alexa Fluor® 647 dye (one unit of
dye in 200 µL of PBS) incubated at 25°C for 20 min
before mounting the coverslip on a glass slide with
Vectashield® mounting medium containing 4′,6-diami
dino-2-phenylindole (DAPI). The confocal images were
observed with a Leica TCS SP-5 confocal microscope
(Wetzlar, Germany). Coumarin-6 was excited with the
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505 nm laser line (emission bandwidth: 515–558 nm),
while DAPI (staining the nuclei of the cells) was excited
with the 405 nm laser line (emission bandwidth: 415–491
nm) and Alexa Fluor® 647 (staining the cell cytoplasm)
was excited with the 633 nm laser line (emission band
width: 645–710 nm).
Flow cytometry was also used to quantify the fluores
cence intensity of coumarin-6 taken up by the cancer cells.
To do so, B16-F10-luc-G5 cells were seeded (1 x 105 cells/
well) and grown for 24 h before treatment with coumarin6 (50 ng/well), which was either entrapped in Tf-bearing
LPN, control LPN or in solution. After 2-h treatment, they
were washed twice with 3 mL cold PBS and harvested
with 250 µL TrypLE® Express. Subsequently, 500 µL
RPMI-1640 medium was added to the cell suspension.
The mean fluorescence intensity (MFI) of coumarin-6
taken up by the cells was measured by flow cytometry,
with a FACSCanto® flow cytometer (BD Biosciences, San
Jose, CA) using a FITC filter (Excmax: 494 nm/Emmax:
520nm). Ten thousand cells (gated events) were counted
for each sample.

Mechanism of Cellular Uptake
To investigate the endocytosis pathway involved in the
cellular uptake of LPN, B16-F10-luc-G5 cells were seeded
at a density of 2 x 105 cells/well in 6-well plates and
incubated for 24 h. Cells were then pre-incubated at 37°C
for 30 min with the endocytosis inhibitors transferrin (50
µM), chlorpromazine (20 µg/mL), filipin (4 µg/mL) and
colchicine (40 µg/mL). The inhibitors were then removed
and replaced with medium containing coumarin-6 (50 ng/
mL) (entrapped in Tf-bearing LPN, control LPN or in
solution) and each inhibitor at the same concentration
(with the exception of chlorpromazine, which was main
tained at a concentration of 5 µg/mL) for a further
2-h incubation at 37°C. The cells were then washed twice
with cold PBS (3 mL) and harvested with TrypLE® Express
(250 µL). The trypsinization reaction was then stopped by
adding medium (500 µL) to the cell suspension. The mean
fluorescence intensity of coumarin-6 taken up by the cells
treated with LPN formulations without any inhibitor was
used as a control and expressed as 100% relative cellular
uptake. Ten thousand cells (gated events) were counted for
each sample.

Anti-Proliferative Activity
The assessment of the anti-proliferative activity of plumba
gin entrapped in LPN formulations was performed using

International Journal of Nanomedicine 2021:16

Dovepress

a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro
mide (MTT) assay. All three cell lines were seeded in 96well plates at a density of 5 x 103 cells/well for 24 h before
treatment with plumbagin at various concentrations (ranging
from 7.81×10−3 to 10 µg/mL), formulated as Tf-bearing
LPN, control LPN, or in solution. Following 24-h treatment,
MTT solution (50 µL, 0.5% w/v in PBS) was added to each
well and incubated with the cells for 4 h. The solution was
then removed and DMSO (200 µL) was added to each well
in order to solubilize the formazan product. The absorbance
of the solution was measured at 570 nm with a Multiskan
Ascent microplate reader (Thermo Labsystems, Beverly,
MA). The anti-proliferative activity of the plumbagin for
mulations was assessed by measuring the growth inhibitory
concentration for 50% of the cell population (IC50) in a MTT
assay. Dose–response curves were fitted to percentage absor
bance values in order to obtain IC50 values (as the results of
three independent experiments, with n=5 for each tested
concentration).

Apoptosis Assay
Cells were seeded at a density of 2 x 105 cells per well in
6-well plates and grown for 24 h before treatment with
plumbagin (1 µg/mL, corresponding to 5 µM), formulated
as Tf-bearing LPN, control LPN or as a solution. After
4-h incubation, the cells were harvested and centrifuged
for 5 min at 2000 rpm (370 g) with an IEC Micromax®
centrifuge (ThermoFisher Scientific, Waltham, MA) before
being labeled with BD Pharmingen® FITC Annexin
V apoptosis detection kit (BD Biosciences, San Jose,
CA), following the protocol provided by the manufacturer.
To do so, the cell pellets were re-suspended in 200 µL 1X
Annexin V Binding Buffer (10X of the buffer containing
0.1 M HEPES/NaOH (pH 7.4), 1.4 M NaCl and 25 mM
CaCl2). Thereafter, 100 µL of cell suspension was trans
ferred to a 5-mL culture tube, followed by 5 µL of FITC
Annexin V labeling reagent and 5 µL of propidium iodide
(PI). Cells were then incubated for 15 min at 20°C and
protected from light. After incubation, Annexin V Binding
Buffer (400 µL) was added to each tube prior to flow
cytometry analysis with a FACSCanto® flow cytometer
(BD Biosciences, San Jose, CA). Ten thousand cells
(gated events) were counted for each sample. The results
were reported as percentages of specific cell populations
(live cells, cells in early or late apoptosis and in necrosis).
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In vivo Tumoricidal Activity
The in vivo experiments were approved by the
University of Strathclyde Animal Welfare and Ethical
Review Body, the local ethics committee. They com
plied with the ARRIVE guidelines and were carried out
in accordance with the United Kingdom Home Office
regulations, described in the “United Kingdom Animals
(Scientific Procedures) Act 1986”.
B16F10-luc-G5 cancer cells in exponential growth
were subcutaneously injected to the flanks of female
immunodeficient BALB/c mice (1×106 cells per flank).
The animals were randomized into groups of five once
tumors were palpable and reached a diameter of 5 mm in
any direction. They were intravenously injected (2 mg/kg
of body weight per injection) with plumbagin entrapped
in Tf-bearing, control lipid–polymer hybrid nanoparticles
or in solution (formulations diluted in glucose 5% solu
tion), once every 2 days for 10 days. The weight of the
animal was measured daily as a surrogate marker of
animal welfare for the whole duration of the experiments.
The tumor volume was determined by caliper measure
ments. The tumor width and length were measured for
each tumor. Their mean was then used in the formula
(volume = d3 x π/6). The results were expressed as
relative tumor volume (rel. Voltx = Voltx/Volt0). The
responses were classified as progressive disease when
the increase in relative tumor volume is higher than
1.2-fold compared with the starting tumor volume, stable
disease when the relative volume is comprised between
0.7 and 1.2 of starting volume, partial response when the
tumor displays a volume reduction of more than 30%
(0–0.7) and complete response when the tumor has
entirely disappeared, as described in the “Response
Evaluation Criteria in Solid Tumors (RECIST)”
guidelines.27

Statistical Analysis
Results were expressed as mean ± standard error of the
mean (S.E.M) in the whole manuscript. Statistical sig
nificance of the data was determined by using one-way
analysis of variance (ANOVA) and Tukey multiple
comparison post-test, with Minitab® 17.1.0 software
(Minitab Ltd., State College, PE). Differences were
considered statistically significant for P values lower
than 0.05.
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Results
Preparation and Optimization of Lipid–
Polymer Hybrid Nanoparticles Entrapping
Plumbagin
The LPN were first prepared by varying the lipid to
PLGA-COOH polymer weight ratio. The lipid to polymer
weight ratios 1:10 and 2:10 resulted in nanoparticles hav
ing a desirable combination of particle hydrodynamic size
(143.8 ± 1.0 nm and 144.4 ± 1.1 nm) and zeta potential
(−57.2 ± 0.3 mV and −58.9 ± 0.8 mV) (Figure 1A). When
increasing the lipid to polymer weight ratio from 4:10 to
10:10, the nanoparticles became larger (169.0 ± 0.7 nm to
183.2 ± 0.9 nm) and were more negatively charged (−63.7
± 0.4 mV to −68.0 ± 0.8 mV). On the other hand, the
entrapment efficiency of plumbagin was stable (around
40%, equivalent to 1 mg plumbagin) at all the tested
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lipid to polymer weight ratios. The lipid to polymer weight
ratio 2:10 was therefore chosen for further studies.
The LPN were then optimized by varying the HPC to
DSPE-PEG2K-MAL molar ratio (Figure 1B). HPC to
DSPE-PEG2K-MAL molar ratios 90:10, 85:15, 80:20 and
70:30 led to smaller nanoparticle hydrodynamic sizes (143.1
± 0.6 nm to 145.8 ± 0.5 nm) and smaller zeta potentials
(−57.2 ± 0.3 mV to −58.5 ± 1.4 mV), while the other ratios
(60:40 and 50:50) resulted in an increase in both the particle
hydrodynamic size (151.4 ± 0.6 nm to 157.0 ± 0.7 nm) and
the zeta potential (−53.0 ± 0.5 mV to −53.3 ± 0.4 mV). The
entrapment efficiency of plumbagin remained constant at
40–50% (equivalent to 1–1.25 mg plumbagin) when increas
ing the HPC to DSPE-PEG2K-MAL molar ratios.
Thus, the optimal formulation of LPN was prepared at the
lipid to PLGA-COOH polymer weight ratio 2:10 and the HPC
to DSPE-PEG2K-MAL molar ratio 70:30, with the concentra
tion of polymer in organic solvent set at 10 mg/mL, plumbagin
loading at 10% of polymer weight and the ratio of water to
organic solvent at 2:1.

Preparation of Transferrin-Bearing Lipid–
Polymer Hybrid Nanoparticles Entrapping
Plumbagin
Tf-bearing LPN entrapping plumbagin have been suc
cessfully prepared, as confirmed by TEM (Figure 2).
The entrapment efficiency of plumbagin in the nanopar
ticles was relatively high, respectively, 46.2 ± 1.0% and
47.0 ± 1.0% for Tf-bearing and control LPN (equivalent
to 1.155 ± 0.025 mg and 1.175 ± 0.025 mg of Tf,
respectively). Tf was conjugated to the LPN at a level
of 72.2 ± 0.5% of the initial Tf (equivalent to 7.2 ±
0.1 mg of Tf).
The grafting of Tf to the surface of the nanoparticles
led to an increase in particle hydrodynamic size of Tfbearing LPN (214.1 ± 1.5 nm, polydispersity: 0.17 ± 0.01)
compared to that of control LPN (145.2 ± 0.6 nm, poly
dispersity: 0.16 ± 0.01). It also increased the net surface
charge of Tf-bearing LPN (−46.6 ± 0.7 mV) in comparison
with control LPN (−66.6 ± 0.6 mV).
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HPC: DSPE-PEG molar ratio
Figure 1 Optimization of lipid–polymer hybrid nanoparticles entrapping plumbagin:
effects of lipid: PLGA-COOH weight ratio (A) and HSPC: DSPE-PEG2000 molar
ratio (B), on particle size, zeta potential and drug entrapment efficiency (n=3).
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Plumbagin Release from the TransferrinBearing Lipid–Polymer Hybrid
Nanoparticles
Tf-bearing and control LPN exhibited a sustained release
of the drug at pHs 7.4 and 5.5 following an initial burst
release, while the drug in solution rapidly diffused through
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Figure 2 TEM pictures of Tf-bearing (left) and control (right) lipid–polymer hybrid nanoparticles entrapping plumbagin (Bar: 200 nm).
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the dialysis membrane to be entirely released within 4
h (Figure 3). The grafting of Tf to the nanoparticles led
to a lower release profile of the drug compared with
control nanoparticles at both the tested pHs (respectively
81.7 ± 1.4% and 95.4 ± 0.7% at pHs 7.4 and 5.5 for Tfbearing LPN, 90.3 ± 1.0% and 98.9 ± 0.2% at pHs 7.4 and
5.5 for control LPN over 24 h).
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The entrapment of plumbagin in Tf-bearing LPN signifi
cantly increased the uptake of plumbagin by the 3 cancer
cell lines compared with control LPN and drug solution
(Figure 4). In B16F10 cells, plumbagin uptake by cells
treated with Tf-bearing LPN was higher than that of con
trol LPN and drug solution, respectively by 1.6-fold and
2.1-fold (1.44 ± 0.06 μg for Tf-bearing LPN, 0.92 ± 0.13
μg for control LPN and 0.70 ± 0.17 μg for plumbagin
solution). It followed a similar trend in A431 cells, with
1.3-fold and 2.7-fold enhancement following treatment
with the targeted formulation compared with control nano
particles and the drug solution (2.46 ± 0.04 μg for Tfbearing LPN, 1.95 ± 0.05 μg for control LPN and 0.92 ±
0.07 μg for plumbagin solution). Treatment of T98G cell
line with Tf-bearing LPN resulted in the highest cellular
uptake of plumbagin amongst the 3 tested cell lines (2.80
± 0.21 μg), which was significantly higher by 1.3-fold and
2-fold than that observed after the treatment with control
nanoparticles and solution (2.24 ± 0.13 μg for control
nanoparticles and 1.43 ± 0.05 μg for plumbagin solution).
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Figure 3 Drug release profile of plumbagin formulated as Tf-bearing lipid–polymer
hybrid nanoparticles (▲, blue), control lipid–polymer hybrid nanoparticles (●, red)
or as free drug in solution (■, black) in phosphate buffer at pH 7.4 (A) and pH 5.5
(B) over 24 h (n=3).
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Figure 4 Cellular uptake of plumbagin (10 µg/well) formulated as Tf-bearing lipid–
polymer hybrid nanoparticles (dark grey), control lipid–polymer hybrid nanoparti
cles (grey) or as solution (white), in B16-F10, A431 and T98G cancer cell lines (n=5)
(*p<0.05 vs Tf-bearing lipid–polymer hybrid nanoparticles).

The cellular uptake of plumbagin loaded in LPN was
comparable to that of coumarin-6, a lipophilic fluorescent
drug model entrapped in LPN, in B16-F10 cells (Figure
5A). The grafting of Tf to the nanoparticles significantly
increased the cellular uptake of coumarin-6 (mean fluor
escence intensity (MFI) of 5784 ± 121 a.u.) by 1.6-fold
compared to control nanoparticles (MFI of 3576 ± 123 a.
u.). However, the highest uptake was observed after the
treatment of the cells with coumarin-6 solution (MFI of
6567 ± 79 a.u.), which might occur by passive diffusion
due to its low molecular weight (350.43 g/mol) and phy
sicochemical properties.
These results were qualitatively confirmed by confocal
microscopy (Figure 5B). The treatment of the cells with
Tf-bearing LPN resulted in a higher cellular uptake of
coumarin-6 compared to that observed in control nanopar
ticles. Cells treated with coumarin-6 solution displayed
coumarin-6-derived fluorescence in their cytoplasm,
which could be explained by the non-specific diffusion
of the drug. Coumarin-6-derived fluorescence was disse
minated in the cytoplasm of B16F10 cells following all
treatments, with no visible co-localization in the nucleus.

Mechanisms of Cellular Uptake
Pre-treatment of B16-F10 cells with 50 µM of free Tf
significantly decreased the uptake of coumarin-6 loaded
in Tf-bearing LPN, with a relative cellular uptake of 79.8
± 0.9% compared with that observed in the cells without
pre-treatment (relative cellular uptake of 100%) (Figure 6).
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Pre-treatment of the cells with chlorpromazine also
resulted in a significant cellular uptake inhibition for
both the targeted and control nanoparticles (respectively
79.7 ± 3.1% and 86.9 ± 1.3%). The uptake of coumarin-6
loaded in Tf-bearing nanoparticles was weakly inhibited
by filipin, decreasing to 92.2 ± 3.0% of that measured in
cells without pre-treatment. By contrast, colchicine only
caused some weak cellular uptake inhibition after treat
ment with control nanoparticles, with a relative cellular
uptake of 93.9 ± 3.0%.
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The anti-proliferative activity of plumbagin was signifi
cantly improved when formulated in LPN in comparison
with the drug solution, by up to 2.5-fold (Table 1, Figure
S1). It was further improved by the conjugation of Tf to
these nanoparticles, by 3.2-fold in B16F10 cells, 2.8-fold
in A431 cells and 3-fold in T98G cells, when compared
with the drug solution. It was not possible to determine the
IC50 following treatment of the cells with blank LPN.
Plumbagin entrapped in transferrin-bearing LPN led to
the highest anti-proliferative efficacy against B16-F10
cells (IC50: 0.16 ± 0.02 µg/mL), followed by A431 cells
(IC50: 0.63 ± 0.0.03 µg/mL), but only exerted a limited
effect in T98G cells (IC50: 2.03 ± 0.15 µg/mL).

Apoptosis Assay
Tf conjugation on plumbagin-loaded LPN significantly
resulted in the highest cellular apoptosis in B16-F10 cells
(Figure 7), with 89.2 ± 0.4% of the cells being apoptotic as
a result of their treatment. By contrast, 80.5 ± 0.6% and 27.5
± 1.0% of the cells were apoptotic following treatment with
the control LPN or the plumbagin solution, respectively.
In A431 cells, the apoptotic effect of the targeted for
mulation was much lower than in B16F10 cells (total
apoptosis of 20.3 ± 1.1%). Control nanoparticles and
plumbagin solution only exerted a very limited apoptotic
effect at the tested conditions on this cell line (total apop
tosis of 13.2 ± 0.3% for control nanoparticles, 7.9 ± 0.9%
for plumbagin solution, similar to the 11.4 ± 0.3% apop
tosis when treated with the blank nanoparticles).
In T98G cells, the apoptotic effect of Tf-bearing LPN
(total apoptosis of 21.0 ± 0.4% cells) was similar to that
observed with A431 cells following treatment with the same
formulation but was not statistically different from that
observed with control nanoparticles or drug solution (total
apoptosis respectively of 17.6 ± 1.5% and 17.1 ± 1.5%).
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Figure 5 Uptake of coumarin-6 loaded in Tf-bearing or control lipid–polymer hybrid nanoparticles, or as solution, by B16-F10 cells: (A) quantitative analysis of the mean
fluorescence intensity of coumarin-6 in the cells, by flow cytometry (n=9) (*p<0.05 vs Tf-bearing lipid–polymer hybrid nanoparticles), (B) qualitative analysis by confocal
microscopy (magnification: 40x).
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Figure 6 Relative cellular uptake of coumarin-6 loaded in Tf-bearing lipid–polymer
hybrid nanoparticles (dark grey) or control lipid–polymer hybrid nanoparticles (light
grey), in the presence of endocytosis inhibitors, in B16-F10 cells (n = 3) (*p<0.05 vs
No inhibitor).

In vivo Tumoricidal Activity
The intravenous injection of plumbagin entrapped in Tfbearing LPN led to an overall reduced B16-F10 tumor
growth. This effect, which occurred within 24 h of the
treatment, was maintained for the whole duration of the
experiment. From Day 6, some of the animals bearing
growing tumors had to be euthanized due to their subcu
taneous tumors reaching the maximum allowed size by our
Project Licence. By contrast, tumors treated with control
LPN, plumbagin solution or blank nanoparticles or left
untreated had a growth rate similar to that of untreated
tumors, and all the animals treated with these formulations
had to be euthanized after 6 days (Figure 8A). No signifi
cant variations of animal body weight or apparent signs of

animal distress were observed during the entire experi
ment, thus demonstrating the good tolerability of all the
treatments by the animals (Figure 8B).
On the last day of the experiment, 40% of tumors
treated with Tf-bearing LPN entrapping plumbagin com
pletely disappeared, while another 10% of tumors showed
a partial regression and 20% were stable (Figure 8C). By
contrast, all the tumors treated with control LPN, plumba
gin solution, blank nanoparticles or left untreated, were
growing.
The enhanced therapeutic efficacy resulting from the
treatment with Tf-bearing LPN loading plumbagin led to
an extended animal survival by 26 days compared to
untreated tumors (Figure 8D). Treatment with both control
nanoparticles and plumbagin solution only extended mice
survival by 2 days compared with untreated animals, thus
emphasizing the crucial need of a tumor-targeted delivery
system for the intravenous delivery of plumbagin to the
tumors.

Discussion
The possibility of using plumbagin for the treatment of
cancer is currently hampered by the inability of this drug
to reach tumors at a therapeutic concentration, in a specific
way, following intravenous injection, therefore resulting
from rapid elimination. To overcome this issue, we
hypothesize that the entrapment of plumbagin in a tumortargeted delivery system would enhance its specific deliv
ery to cancer cells and enhance its therapeutic efficacy,
while reducing the secondary effects of the drug to normal
tissues.
In this study, plumbagin was entrapped in novel trans
ferrin-bearing lipid-polymer hybrid nanoparticles. PLGACOOH, a hydrophobic and biodegradable polymer, was

Table 1 Anti-Proliferative Efficacy of Plumbagin Loaded in Tf-Bearing LPN, Control LPN or in Solution, in B16-F10, A431 and T98G
Cells (Results Expressed as IC50 ± SEM) (n=15)
Cell Lines

IC50 (µg/mL) (Mean ± S.E.M.)
Tf-LPN

Ctrl LPN

Plumbagin Solution

Blank LPN

B16-F10

0.16 ± 0.02

0.32 ± 0.01

0.51 ± 0.02

n.d.

A431

0.63 ± 0.03

1.61 ± 0.28

1.78 ± 0.20

n.d.

T98G

2.03 ± 0.15

2.40 ± 0.49

6.19 ± 0.20

n.d.

Abbreviations: ANOVA, one-way analysis of variance; DAPI, 4′,6-diamidino-2-phenylindole; DMEM, Dulbecco’s Modified Eagle Medium; DSPE-PEG2K-MAL, 1,2-distearoylsn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene glycol)-2000]; EE, entrapment efficiency; EPR, enhanced permeability and retention; FBS, fetal bovine serum;
FITC, fluorescein isothiocyanate; HPC, hydrogenated phosphatidylcholine; LPN, lipid–polymer hybrid nanoparticles; MAPK, mitogen-activated protein kinase; mTOR,
mammalian target of rapamycin; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NF-kB, nuclear factor-κB; PBS, phosphate buffer saline; PEG, poly
ethylene glycol; PI, propidium iodide; PI3K, phosphoinositide 3-kinase; PKB/AKT, protein kinase B/Akt; PLGA, poly(lactic-co-glycolic acid); PLGA-COOH, acid-terminated
poly(lactide-co-glycolide); RPMI-1640, Roswell Park Memorial Institute 1640; RECIST, Response Evaluation Criteria in Solid Tumors; S.E.M, standard error of the mean;
STAT3, signal transducer and activator of transcription 3; TEM, transmission electron microscopy; Tf, transferrin.
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Figure 7 Apoptosis induction of B16-F10, A431 and T98G cells following treatment with plumbagin (1 µg/mL, corresponding to 5 µM) loaded in Tf-bearing or control lipid–
polymer hybrid nanoparticles, or in solution. (A) Flow cytometric plots showing the percentage of specific cell populations in live, early apoptosis, late apoptosis and
necrosis. (B) Percentage of total apoptotic cells (n = 3) (*P< 0.05 vs Tf-bearing lipid–polymer hybrid nanoparticles).
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Figure 8 (A) Tumor growth studies in a B16-F10 murine model following systemic injection of transferrin-bearing lipid–polymer hybrid nanoparticles loading plumbagin
(2 mg/kg of body weight/injection) (■, dark green), control lipid–polymer hybrid nanoparticles entrapping plumbagin (●, red), blank lipid–polymer hybrid nanoparticles (▲,
blue), plumbagin solution (▼, orange), untreated tumors (■, black) (relative tumor volume rel. Voltx = Voltx/Volt0) (n=10). (B) Variations of the body weight of the mice
during the treatment (Color coding as in (A)). (C) Overall tumor response to treatments at the end of the study (green: complete response, yellow: partial response,
orange: stable response and red: progressive response). (D) Time to disease progression. The Y-axis indicates the proportion of surviving mice over time. Animals were
removed from the study once their tumor size reached 10 mm diameter in any direction. (Color coding as in (A)).

used to form the polymeric core of the hybrid nanoparti
cles which entrapped plumbagin, surrounded by a lipid
monolayer consisting of hydrogenated phosphatidylcho
line and DSPE-PEG2K-MAL that provided a stealth effect
and facilitated surface modification. The LPN were suc
cessfully prepared by one-step nanoprecipitation, where
the PLGA polymer in water-miscible organic solvent was
mixed with the aqueous lipid dispersion to allow selfassembling. This method was more efficient, required
less time and less energy than the two-step method,
where lipid vesicles and polymeric nanoparticles were
separately prepared before being mixed or ultrasonicated,
and then homogenized.28 We chose to use PLGA-COOH
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for this study instead of PLGA with an ester end group, as
the presence of one or two charged end groups per poly
mer allows a size reduction of the polymer-based
nanoparticles.29
The optimal formulation of LPN was found at low lipid
to polymer weight ratios (10–20%), which can be
explained by the fact that the entire surface of the PLGACOOH polymer core was covered by the lipids used at
these ratios.17 At high lipid to polymer weight ratios, the
excess HPC and DSPE-PEG2K-MAL lipids can sponta
neously form liposomes, thus resulting in an increase of
the overall measured hydrodynamic size of LPN and
a decrease of their zeta potential value. In addition, when
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maintaining the lipid to polymer weight ratio at 20%, the
increase of DSPE-PEG2K-MAL (40–50 mol%) had an
impact on both the size and zeta potential of the delivery
systems. This might be due to the particular conformations
of PEG chains at different grafting densities.30,31 At low
density (10–30 mol%), the PEG chains formed
a mushroom configuration which has a limited impact on
particle size and zeta potential. However, at high density,
PEG chains tend to stretch and form a brush structure,
leading to an increase in the size and zeta potential of the
particles.
The conjugation of Tf to the LPN was achieved by
using the thiol–maleimide “click” reaction, a widely used
thiol-based bioconjugation technique for conjugating anti
bodies, proteins or peptides to delivery systems due to its
compatibility with aqueous condition, rapid reaction (with
out heat or catalysts) and high selectivity.32
Entrapment efficiency is a very important parameter to
take into account in the design of drug delivery systems. In
our study, plumbagin was highly loaded in both targeted
and control LPN. Plumbagin has previously been reported
to be entrapped in various delivery systems, such as nio
somes, polymeric nanoparticles, micelles and PEGylated
liposomes, with a percentage entrapment efficiency vary
ing from 38% to 98%.12,13,16,33,34 We could not find any
publications reporting the entrapment efficiency of plum
bagin entrapped in LPN to compare with our results.
Tf-bearing LPN displayed sizes below the cut-off size
for extravasation across tumor vasculature,35 enabling
them to efficiently deliver the drug to the tumors. They
were spherical, which facilitates their uptake by cancer
cells compared to other morphologies, such as ellipsoid
and worm-like.36,37 The size of the LPN obtained from the
TEM images was found to be smaller than that observed
with photon correlation spectroscopy, as TEM imaging
technique involves drying of the samples before measure
ment, unlike hydrodynamic size measurement through
photon correlation spectroscopy using a Zetasizer.
They were bearing negative surface charges that were
higher than that observed on the surface of control LPN.
This was most likely due to the presence of the positively
charged amino acids of Tf (zeta potential of −25.0 ± 3.6
mV) and ferrous iron (Fe2+) in the protein.38 These nega
tive charges, together with the PEGylation of the LPN,
would prevent the opsonization of the nanoparticles by
serum proteins, therefore avoiding a rapid clearance by
the mononuclear phagocytic system and prolonging their
blood circulation time.39,40 In addition, the Tf-bearing
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LPN can be considered as highly stable colloidal systems
as their zeta potential value is lower than −30 mV.41
Furthermore, the changes in size and drug leakage of Tfbearing and control LPN were low during 4 weeks of
storage at 4°C in PBS (data not shown). Tf-bearing LPN,
therefore, have the required physicochemical characteris
tics for being efficacious delivery systems for plumbagin.
The LPN showed a sustained release profile of plum
bagin following an initial burst effect corresponding to the
release of plumbagin adsorbed on the lipid surface or
entrapped in the outer layer of polymer core.42 The sub
sequent sustained release of plumbagin may occur by
diffusion of the drug entrapped in the polymeric core
through water-filled pores, which is the most common
mechanism of release reported in polymer-based
nanoparticles.43 In addition, Tf-bearing LPN showed
a slower release of plumbagin compared with control
LPN, probably because the conjugated Tf prevented the
drug to freely diffuse out of the polymer core.
In vitro, the cellular uptake studies showed that the
grafting of Tf to LPN significantly increased the uptake
of the drug compared with control LPN and solution on
the three cancer cell lines. Similar results were obtained
when replacing plumbagin with the lipophilic fluorescent
drug model coumarin-6. These results were in accordance
with previously published data by Guo and colleagues,
who showed that the use of Tf as a targeting ligand on
lipid-coated PLGA nanoparticles entrapping doxorubicin
improved the cellular uptake of doxorubicin by 2.8-fold
compared with non-targeted nanoparticles on A549 cells.44
This outcome was also reported by Zheng and colleagues,
who showed that Tf-conjugated lipid-coated PLGA nano
particles entrapping calcein were more efficiently taken up
by SKBR-3 breast cancer cells than with the non-targeted
formulation.45
The uptake of Tf-conjugated LPN was partially inhibited
by free Tf, chlorpromazine and filipin, while non-targeted
LPN has its cellular uptake partially blocked by chlorpro
mazine and colchicine. Pre-treatment of B16-F10 cells with
Tf resulted in competition between Tf-bearing LPN and Tf,
suggesting that the internalization of Tf-bearing LPN is
partly due to Tf receptors-mediated endocytosis. This out
come is in agreement with previous results published by
Zheng and colleagues, who revealed that the cellular uptake
of Tf-bearing, lipid-coated PLGA nanoparticles carrying an
aromatase inhibitor was reduced by the excess free Tf in the
culture medium.45 Both chlorpromazine and filipin are pino
cytosis inhibitors: chlorpromazine inhibits clathrin-mediated
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endocytosis, which is a major pathway for internalization of
various nanomedicines,46 whereas filipin has been reported
to block the caveolae-mediated process, a clathrinindependent endocytosis.47 Colchicine has previously been
shown to inhibit micropinocytosis, a non-specific process to
internalize particles and fluids.48 These results, therefore,
confirm the involvement of clathrin-mediated endocytosis,
a requisite for Tf receptor-mediated endocytosis, and caveo
lae-mediated endocytosis in the internalization of Tf-bearing
LPN.
The conjugation of Tf to LPN led to an increase of
the anti-proliferative efficacy of plumbagin-loaded LPN
in all the three cancer cell lines. This might be due to
the enhanced cellular uptake when treated with plumba
gin formulated as Tf-conjugated LPN. The entrapment
of plumbagin in various delivery systems has previously
been reported to improve its therapeutic efficacy. For
instance, micelles entrapping plumbagin improved its
anti-proliferative efficacy by 2.1-fold compared with
drug solution on MCF-7 cells.34 In another study,
Pawar and colleagues have demonstrated that loading
plumbagin into folic acid-bearing D-α-tocopheryl PEG
1000 succinate nanomicelles was able to improve its
anti-proliferative activity on MCF-7 cells, respectively
by 2.4-fold and 4.1-fold in comparison with unconju
gated formulation and drug solution,12 in line with our
results.
The loading of plumbagin in Tf-conjugated LPN also
increased apoptosis in B16-F10 and A431 cell lines,
unlike drug solution. This effect, more pronounced on
B16-F10 than on A431 cells, was probably the conse
quence of an increased sensitivity of B16-F10 cells
toward plumbagin-mediated apoptosis. Our results cor
related well with previous reports by Duraipandy and
colleagues, who demonstrated that the treatment of
A431 cells with plumbagin loaded in silver nanocages
resulted in the apoptosis of the cells, while plumbagin
solution did not show any effect.49 In another work,
silver nanoparticles entrapping plumbagin was shown
to induce apoptosis in HeLa cells, unlike plumbagin
solution.50 However, in T98G cells, Tf-bearing LPN
entrapping plumbagin did not cause apoptosis at the
tested experimental conditions. T98G cells, known to
be highly resistant to alkylating agents such as temozo
lomide, the frontline treatment for glioblastoma
multiforme,51 might also resist the alkylating properties
of plumbagin.52
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In vivo, we demonstrated that the systemic injection of
plumbagin loaded in Tf-conjugated LPN resulted in com
plete tumor eradication for 40% of B16-F10 tumors and
tumor regression for 10% of the tumors. To our knowledge,
this is the first time that intravenously administered targeted
plumbagin was shown to result in regression of tumors in
mice, and even to complete tumor disappearance in some
instances over 30 days. Previous studies have demonstrated
that plumbagin loaded in various delivery systems was able
to slow down the growth of tumors, but without tumor
regression or disappearance, even when using larger doses
compared to the 2 mg/kg used in our study. For example, the
intravenous administration of plumbagin loaded in tempera
ture-sensitive liposomes (6 mg/kg with localized hyperther
mia treatment at 43°C)14 or in PEGylated liposomes (2 mg/
kg)13 led to a slowdown of the growth of B16F1 melanoma
tumors, compared with that observed with the drug solution.
Similarly, the intramuscular injection of plumbagin loaded
in chitosan-based microspheres to C57BL/6J mice bearing
B16F1 tumors significantly increased tumor inhibition and
animals’ life-span by 30% compared to free plumbagin.53 In
another study, the subcutaneous administration of plumba
gin loaded in PLGA microspheres (10 mg/kg) to BALB/C
mice led to a decrease in tumor growth of sarcoma-180
tumors compared with that obtained when treated with
plumbagin solution.15 In addition, we previously demon
strated that the intravenous injection of transferrinconjugated liposomes loading plumbagin resulted in tumor
suppression for 10% of B16-F10 tumors and tumor regres
sion for another 10% of the tumors, but these effects lasted
only for a limited duration of 10 days.54 Similarly, we also
demonstrated that transferrin-bearing PLGA-PEG nanopar
ticles led to the complete tumor eradication for only 10% of
B16-F10 tumors and regression of 30% of the tumors.55 The
strong anti-tumor effect of Tf-bearing lipid-polymer hybrid
nanoparticles over the Tf-bearing liposomes may be
explained as follows: 1) the lipid layer enhances the affinity
of the delivery system to the lipid cell membrane, and thus
increases the delivery of plumbagin to the tumors, 2) the
polymeric core of the LPN provides a good stability in the
blood following intravenous administration compared to
liposomes, 3) the unique structure of the LPN further
delayed the release of the drug compared to that observed
with the liposome formulation, thereby prolonging the cir
culation half-life and increasing the accumulation of the
drug in tumors.
The most striking effect of the tumor-targeted lipid–
polymer hybrid nanoparticles was the induction of the
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regression of the tumors within one day after treatment
and the complete disappearance of the tumors for some
animals within 10 days of treatment. There may be scope
to further enhance the in vivo efficacy of these very safe
delivery systems by increasing the dose, the frequency and
the overall duration of the treatment, hopefully leading to
a further improved therapeutic effect.

Conclusion
We have demonstrated for the first time that novel Tfconjugated lipid–polymer hybrid nanoparticles loading
plumbagin and administered intravenously resulted in
a complete disappearance of 40% of B16-F10 melanoma
tumors and regression of 10% of the tumors without any
signs of animal distress. In contrast, all the tumors treated
with control nanoparticles and plumbagin solution, or left
untreated, were growing. This study provides a proof of
principle that the loading of plumbagin in a tumor-targeted
delivery system is a highly promising strategy for cancer
treatment which should be further investigated to optimize
its potential.
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